Status:
UNKNOWN
Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy
Lead Sponsor:
Beijing Friendship Hospital
Collaborating Sponsors:
Peking University First Hospital
Peking University People's Hospital
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-75 years
Brief Summary
Patients who have completed 3 years follow-up of the past Beijing Science and Technology Commission Research will receive another 7-years anti-viral therapy. Patients will be assessed at baseline and ...
Detailed Description
Patients who have completed 3 years follow-up of the past Beijing Science and Technology Commission Research will receive another 7-years anti-viral therapy. Patients will be assessed at baseline and ...
Eligibility Criteria
Inclusion
- Patients who have participated in the research funded by Beijing science and Technology Commission and have completed 156 weeks follow-up.
- Patients comply with the requirements of the trail voluntarily
- Written informed consent
Exclusion
- Pregnant woman or patient with severe disease
- Patients with poor adherence to the study
- Patients not suitable for the study evaluated by the investigator
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT03366571
Start Date
January 1 2016
End Date
December 1 2024
Last Update
April 14 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
2
Beijing Ditan Hospital
Beijing, Beijing Municipality, China
3
Beijing YouAn Hospital
Beijing, Beijing Municipality, China
4
Peking University People's Hopsital
Beijing, Beijing Municipality, China